Annovis Bio is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Co.'s primary compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. For acute indications, Co. is developing ANVS405, focused on protecting the brain after traumatic brain injury and/or stroke. Co. is also developing its compound, ANVS301, to increase cognitive capability in later stages of AD and dementia. The ANVS stock yearly return is shown above.
The yearly return on the ANVS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ANVS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|